{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T17:24:27Z","timestamp":1776878667179,"version":"3.51.2"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Heart and Diabetes Centre North Rhine-Westphalia (DKZ NRW)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mavacamten is the first approved myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), addressing hypercontractility and left ventricular outflow tract (LVOT) obstruction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study evaluates left ventricular performance by non-invasive measurements of pressure\u2013strain loops in patients treated with Mavacamten.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In 36 symptomatic oHCM patients, pressure\u2013strain analysis was performed prior to 3 and 12\u00a0months after Mavacamten therapy. Echocardiographic measurements included LVOT gradient, left ventricular ejection fraction (LVEF), global longitudinal strain (GLS), left atrial strain (LAS), peak strain time dispersion (PSD), and myocardial work parameters (global work index (GWI), global constructive work (GCW), global wasted work (GWW), and global work efficiency (GWE)). Clinical status was evaluated using the New York Heart Association (NYHA) class and stress biomarkers (NTproBNP and high-sensitivity troponin I).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Mavacamten therapy significantly reduced LVOT gradients at rest and under provocation. Gradients decreased from 69\u2009\u00b1\u200936 to 24\u2009\u00b1\u200927\u00a0mmHg (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) at 3\u00a0months and further to 11\u2009\u00b1\u20096\u00a0mmHg (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003) at 12\u00a0months. Provoked gradients decreased from 113\u2009\u00b1\u200933 to 50\u2009\u00b1\u200931\u00a0mmHg (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) at 3\u00a0months and to 31\u2009\u00b1\u200919\u00a0mmHg (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01) at 12\u00a0months. Clinical symptoms also improved. LVEF was 68\u2009\u00b1\u20096% at baseline and decreased mildly to 62\u2009\u00b1\u20095% (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003), while GLS and LAS remained unchanged. PSD decreased mildly from 116\u2009\u00b1\u200956 to 97\u2009\u00b1\u200936\u00a0ms and further to 93\u2009\u00b1\u200938\u00a0ms, but this was not statistically significant (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.07). Under Mavacamten, GWE remained stable. In contrast, GWI, GCW, and GWW decreased significantly from baseline to 3\u00a0months (GWI, 2098\u2009\u00b1\u2009700 to 1610\u2009\u00b1\u2009440\u00a0mmHg%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001; GCW, 2514\u2009\u00b1\u2009776 to 1951\u2009\u00b1\u2009466\u00a0mmHg%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001; GWW, 312\u2009\u00b1\u2009163 to 249\u2009\u00b1\u2009177\u00a0mmHg%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003), with only mild, non-significant further reductions at 12\u00a0months (1538\u2009\u00b1\u2009402, 1901\u2009\u00b1\u2009380, and 207\u2009\u00b1\u2009124\u00a0mmHg%, respectively;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.67,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.74,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.30).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Myocardial work indices derived from non-invasive pressure\u2013strain analysis were feasible to obtain in patients with oHCM in this study. Mavacamten therapy decreases workload index, constructive and wasted work, and synchronizes myocardial contractility, reflecting normalization of myocardial energetics. These findings reinforce the role of Mavacamten as a targeted therapy in oHCM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00392-026-02855-0","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T09:38:38Z","timestamp":1771493918000},"page":"875-886","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mavacamten optimizes myocardial work in patients with obstructive hypertrophic cardiomyopathy: a non-invasive pressure\u2013strain analysis"],"prefix":"10.1007","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7445-5986","authenticated-orcid":false,"given":"S.","family":"Scholtz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Copp\u00e9e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Mohemed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Potratz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Langkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Rudolph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Maack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Scholtz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Sequeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-C.","family":"Reil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"2855_CR1","doi-asserted-by":"publisher","first-page":"e558","DOI":"10.1161\/cir.0000000000000937","volume":"142","author":"SR Ommen","year":"2020","unstructured":"Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, Evanovich LL, Hung J, Joglar JA, Kantor P et al (2020) 2020 AHA\/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American heart association joint committee on clinical practice Guidelines. Circulation 142:e558\u2013e631. https:\/\/doi.org\/10.1161\/cir.0000000000000937","journal-title":"Circulation"},{"key":"2855_CR2","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, Bezzina CR, Biagini E, Blom NA, de Boer RA et al (2023) 2023 ESC Guidelines for the management of cardiomyopathies: developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC). Eur Heart J 44:3503\u20133626. https:\/\/doi.org\/10.1093\/eurheartj\/ehad194","journal-title":"Eur Heart J"},{"key":"2855_CR3","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/S0140-6736(16)31321-6","volume":"389","author":"J Veselka","year":"2017","unstructured":"Veselka J, Anavekar NS, Charron P (2017) Hypertrophic obstructive cardiomyopathy. Lancet 389:1253\u20131267. https:\/\/doi.org\/10.1016\/S0140-6736(16)31321-6","journal-title":"Lancet"},{"key":"2855_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.101728","volume":"4","author":"J-C Reil","year":"2025","unstructured":"Reil J-C, Sequeira V, Reil G-H, Scholtz S, Rudolph V, Maack C, Serruys P, Steendijk P (2025) Investigating the Anrep effect in hypertrophic obstructive cardiomyopathy with invasive pressure-volume analysis. JACC Adv 4:101728. https:\/\/doi.org\/10.1016\/j.jacadv.2025.101728","journal-title":"JACC Adv"},{"key":"2855_CR5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1161\/circresaha.123.323173","volume":"134","author":"V Sequeira","year":"2024","unstructured":"Sequeira V, Maack C, Reil GH, Reil JC (2024) Exploring the connection between relaxed myosin states and the Anrep effect. Circ Res 134:117\u2013134. https:\/\/doi.org\/10.1161\/circresaha.123.323173","journal-title":"Circ Res"},{"key":"2855_CR6","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1136\/hrt.2007.139535","volume":"94","author":"P Steendijk","year":"2008","unstructured":"Steendijk P, Meliga E, Valgimigli M, Ten Cate FJ, Serruys PW (2008) Acute effects of alcohol septal ablation on systolic and diastolic left ventricular function in patients with hypertrophic obstructive cardiomyopathy. Heart 94:1318\u20131322. https:\/\/doi.org\/10.1136\/hrt.2007.139535","journal-title":"Heart"},{"key":"2855_CR7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.116.005604","volume":"10","author":"A G\u00fc\u00e7l\u00fc","year":"2017","unstructured":"G\u00fc\u00e7l\u00fc A, Knaapen P, Harms Hendrik J H, Parbhudayal Rahana Y P, Michels M, Lammertsma Adriaan A L, van Rossum Albert C v, Germans T, van der Velden J (2017) Disease stage-dependent changes in cardiac contractile performance and oxygen utilization underlie reduced myocardial efficiency in human inherited hypertrophic cardiomyopathy. Circ Cardiovasc Imaging 10:e005604. https:\/\/doi.org\/10.1161\/CIRCIMAGING.116.005604","journal-title":"Circ Cardiovasc Imaging"},{"key":"2855_CR8","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1161\/01.CIR.79.4.766","volume":"79","author":"RO Cannon","year":"1989","unstructured":"Cannon RO, McIntosh CL, Schenke WH, Maron BJ, Bonow RO, Epstein SE (1989) Effect of surgical reduction of left ventricular outflow obstruction on hemodynamics, coronary flow, and myocardial metabolism in hypertrophic cardiomyopathy. Circulation 79:766\u2013775. https:\/\/doi.org\/10.1161\/01.CIR.79.4.766","journal-title":"Circulation"},{"key":"2855_CR9","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1126\/science.aad3456","volume":"351","author":"EM Green","year":"2016","unstructured":"Green EM, Wakimoto H, Anderson RL, Evanchik MJ, Gorham JM, Harrison BC, Henze M, Kawas R, Oslob JD, Rodriguez HM et al (2016) A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science 351:617\u2013621. https:\/\/doi.org\/10.1126\/science.aad3456","journal-title":"Science"},{"key":"2855_CR10","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.63703","author":"S Nag","year":"2021","unstructured":"Nag S, Trivedi DV (2021) To lie or not to lie: super-relaxing with myosins. Elife. https:\/\/doi.org\/10.7554\/eLife.63703","journal-title":"Elife"},{"key":"2855_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","volume":"80","author":"MY Desai","year":"2022","unstructured":"Desai MY, Owens A, Geske JB, Wolski K, Naidu SS, Smedira NG, Cremer PC, Schaff H, McErlean E, Sewell C et al (2022) Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy. J Am Coll Cardiol 80:95\u2013108. https:\/\/doi.org\/10.1016\/j.jacc.2022.04.048","journal-title":"J Am Coll Cardiol"},{"key":"2855_CR12","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/s0140-6736(20)31792-x","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, Saberi S, Lakdawala NK, Wheeler MT, Owens A et al (2020) Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 396:759\u2013769. https:\/\/doi.org\/10.1016\/s0140-6736(20)31792-x","journal-title":"Lancet"},{"key":"2855_CR13","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1161\/CIRCIMAGING.109.862334","volume":"2","author":"T Stanton","year":"2009","unstructured":"Stanton T, Leano R, Marwick TH (2009) Prediction of all-cause mortality from global longitudinal speckle strain. Circ Cardiovasc Imaging 2:356\u2013364. https:\/\/doi.org\/10.1161\/CIRCIMAGING.109.862334","journal-title":"Circ Cardiovasc Imaging"},{"key":"2855_CR14","doi-asserted-by":"publisher","first-page":"H743","DOI":"10.1152\/ajpheart.00828.2014","volume":"308","author":"A Kov\u00e1cs","year":"2015","unstructured":"Kov\u00e1cs A, Ol\u00e1h A, Lux \u00c1, M\u00e1ty\u00e1s C, N\u00e9meth BT, Kellermayer D, Ruppert M, T\u00f6r\u00f6k M, Szab\u00f3 L, Meltzer A et al (2015) Strain and strain rate by speckle-tracking echocardiography correlate with pressure-volume loop-derived contractility indices in a rat model of athlete\u2019s heart. Am J Physiol Heart Circ Physiol 308:H743\u2013H748. https:\/\/doi.org\/10.1152\/ajpheart.00828.2014","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"8","key":"2855_CR15","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1093\/ejechocard\/jep095","volume":"10","author":"E Donal","year":"2009","unstructured":"Donal E, Bergerot C, Thibault H, Ernande L, Loufoua J, Augeul L, Ovize M, Derumeaux G (2009) Influence of afterload on left ventricular radial and longitudinal systolic functions: a two-dimentional strain imaging study. Eur J Echocardiogr 10(8):914\u2013921. https:\/\/doi.org\/10.1093\/ejechocard\/jep095","journal-title":"Eur J Echocardiogr"},{"key":"2855_CR16","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1093\/eurheartj\/ehs016","volume":"33","author":"K Russell","year":"2012","unstructured":"Russell K, Eriksen M, Aaberge L, Wilhelmsen N, Skulstad H, Remme EW, Haugaa KH, Opdahl A, Fjeld JG, Gjesdal O et al (2012) A novel clinical method for quantification of regional left ventricular pressure\u2013strain loop area: a non-invasive index of myocardial work. Eur Heart J 33:724\u2013733. https:\/\/doi.org\/10.1093\/eurheartj\/ehs016","journal-title":"Eur Heart J"},{"key":"2855_CR17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/ehjci\/jeaa301","volume":"22","author":"OA Smiseth","year":"2021","unstructured":"Smiseth OA, Donal E, Penicka M, Sletten OJ (2021) How to measure left ventricular myocardial work by pressure-strain loops. Eur Heart J Cardiovasc Imaging 22:259\u2013261. https:\/\/doi.org\/10.1093\/ehjci\/jeaa301","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2855_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2025-003192","volume":"12","author":"S Scholtz","year":"2025","unstructured":"Scholtz S, Copp\u00e9e C, Mohemed K, Potratz M, Sequiera V, Rudolph V, Scholtz W, Reil J-C (2025) Mavacamten maintenance dose determination: insights into individualised therapy for hypertrophic cardiomyopathy. Open Heart 12:e003192. https:\/\/doi.org\/10.1136\/openhrt-2025-003192","journal-title":"Open Heart"},{"key":"2855_CR19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.121.013712","volume":"15","author":"FJ Olsen","year":"2022","unstructured":"Olsen FJ, Skaarup KG, Lassen MCH, Johansen ND, Sengel\u00f8v M, Jensen GB, Schnohr P, Marott JL, S\u00f8gaard P, Gislason G et al (2022) Normal values for myocardial work indices derived from pressure-strain loop analyses: from the CCHS. Circ Cardiovasc Imaging 15:e013712. https:\/\/doi.org\/10.1161\/CIRCIMAGING.121.013712","journal-title":"Circ Cardiovasc Imaging"},{"key":"2855_CR20","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1093\/eurheartj\/ehaa603","volume":"41","author":"JM Aalen","year":"2020","unstructured":"Aalen JM, Donal E, Larsen CK, Duchenne J, Lederlin M, Cvijic M, Hubert A, Voros G, Leclercq C, Bogaert J et al (2020) Imaging predictors of response to cardiac resynchronization therapy: left ventricular work asymmetry by echocardiography and septal viability by cardiac magnetic resonance. Eur Heart J 41:3813\u20133823. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa603","journal-title":"Eur Heart J"},{"key":"2855_CR21","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1093\/ehjci\/jeaa257","volume":"22","author":"R Jain","year":"2021","unstructured":"Jain R, Bajwa T, Roemer S, Huisheree H, Allaqaband SQ, Kroboth S, Perez Moreno AC, Tajik AJ, Khandheria BK (2021) Myocardial work assessment in severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J Cardiovasc Imaging 22:715\u2013721. https:\/\/doi.org\/10.1093\/ehjci\/jeaa257","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2855_CR22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1093\/ehjci\/jead227","volume":"25","author":"D Ribic","year":"2024","unstructured":"Ribic D, Remme EW, Smiseth OA, Massey RJ, Eek CH, Kvitting JP, Gullestad L, Broch K, Russell K (2024) Non-invasive myocardial work in aortic stenosis: validation and improvement in left ventricular pressure estimation. Eur Heart J Cardiovasc Imaging 25:201\u2013212. https:\/\/doi.org\/10.1093\/ehjci\/jead227","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2855_CR23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/ehjci\/jead236","volume":"25","author":"A Batzner","year":"2024","unstructured":"Batzner A, Hahn P, Morbach C, St\u00f6rk S, Maack C, Verheyen N, Gerull B, Frantz S, Seggewiss H (2024) Non-invasive estimation of left ventricular systolic peak pressure: a prerequisite to calculate myocardial work in hypertrophic obstructive cardiomyopathy. Eur Heart J Cardiovasc Imaging 25:213\u2013219. https:\/\/doi.org\/10.1093\/ehjci\/jead236","journal-title":"Eur Heart J Cardiovasc Imaging"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-026-02855-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-026-02855-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-026-02855-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T06:55:55Z","timestamp":1776236155000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-026-02855-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2855"],"URL":"https:\/\/doi.org\/10.1007\/s00392-026-02855-0","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SS received travel expenses and speaker honoraria from Bristol Myers Squibb. VS has received research funding from Bristol Myers Squibb unrelated to this work. All other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}